文献速递病毒性肝炎

卢旺达直接抗病毒药物治疗慢性丙型肝炎的有效性:回顾性研究

Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

符合方案分析的590例中SVR12达92%,意向性分析全人群SVR12为60%,非病毒学失败占34%。DAA经国家卫生系统实施有效,但需分散治疗和加强随访。

要点

  • 符合方案分析中SVR12达92%,病毒学失败8%。
  • 意向性分析全人群SVR12为60%,非病毒学失败34%。
  • 治疗前HCV RNA高于中位数分界与病毒学失败相关。

核心结论

  • DAA经卢旺达国家卫生系统实施对慢性丙肝治疗有效。

主要发现

  • 590例完成治疗并有SVR12结果者中,540例(92%)达SVR12,50例(8%)病毒学失败。
  • 纳入全部患者的意向性分析中,540例(60%)达SVR12,304例(34%)为非病毒学失败,50例(6%)病毒学失败。
  • 治疗前HCV RNA高于中位数分界与病毒学失败相关。
  • 西部省患者较基加利患者更易发生非病毒学失败,可能与需5-7小时路程获取检测和治疗有关。

临床怎么用

  • 在撒哈拉以南非洲国家卫生系统内可实施DAA治疗并获较高符合方案SVR12。
  • 需关注治疗前高HCV RNA者的病毒学失败风险。
  • 分散治疗与加强随访可能改善治疗可及性和结果。

局限性

  • 304例无SVR12结果者被归类为非病毒学失败,无法确定病毒清除。
  • 为回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct-acting antivirals (DAAs) are becoming accessible in sub-Saharan Africa. This study examined the effectiveness of DAAs in patients treated through the Rwandan national health system and identified factors associated with treatment outcomes. METHODS: This retrospective study used data from the national hepatitis C virus (HCV) program for patients who initiated DAAs between November 2015 and March 2017. Sustained virological response at 12 weeks after treatment (SVR12) was the primary outcome. Logistic regression models were fit to estimate the relationship between patients' clinical and demographic characteristics and treatment outcome. RESULTS: 894 patients started treatment during the study period; 590 completed treatment and had SVR12 results. Among the 304 patients without SVR12 results, 48 were lost to follow-up and 256 had no SVR12 results but clinical data indicated they likely completed treatment; these patients were classified as nonvirological failure because viral clearance could not be determined. In a per-protocol analysis of 590 patients with SVR12 results, SVR12 was achieved in 540 (92%), and virological failure occurred in 50 (8%). Pretreatment HCV RNA above the median split was associated with virological failure. Intention-to-treat analyses including all patients showed that SVR12 was achieved in 540 (60%), with nonvirological failure in 304 (34%) and virological failure in 50 (6%). Patients in Western Province were more likely to experience nonvirological failure than patients in Kigali, likely owing to the 5-7-hour travel required to access testing and treatment. CONCLUSIONS: DAAs were effective when implemented through the Rwandan national health system. Decentralization and enhanced financing are underway in Rwanda, which could improve access to treatment and follow-up as the country prepares for HCV elimination.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nsanzimana S, Penkunas MJ, Liu CY, et al. Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study. Clin Infect Dis. 2021. PMID: 32505127. doi:10.1093/cid/ciaa701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。